Medical & Engineering Publishers,
Inc. PO Box 74, Sunshine, MD 20833-0074
Phone/Fax: 1-888-380-1930
Home : Books :
THROMBOSIS RESEARCH AND TREATMENT, BENCH TO
BEDSIDE
Jafar Vossoughi, Jawed Fareed, Shaker A Mousa, John W Karanian
(Editors)
624 + xvi Pages; 6 x 9˝ Hardcover, April
2004
138 illustrations (8 color plates), 68 tables, and over 1,500 References
ISBN: 1-930636-03-2
Published by:MEDICAL and ENGINEERING
PUBLISHERS, Inc
Table of Contents
Part I: Clinical Perspectives And IN VIVO
Studies
1.Thrombosis in the New Millennium; Arthur A Sasahara 2.Clinical Development of Argatroban; Masanori Osakabe, Hikari Watanabe 3. Phase
I, Study in Healthy Male Caucasian Subjects to Investigate the Safety,
Tolerability, Pharmaco-Kinetics and
Pharmacodynamics of Ascending Single Intravenous Doses of a Novel Anti-Xa
Agent, JTV-803;
Francois E Wilhelm 4.Timing of Thromboprophylaxis and Out of Hospital Prophylaxis with Low
Molecular
Weight Heparin; Russell D Hull, Graham F Pineo, Natasha Burke, Vinay Bharadia 5.Outpatient Anticoagulation: Innovative Strategies and Point of Care INR
Testing;
Wendy A Leong 6.The Leap from Proof-of-Concept to Registration: Lessons from the Past
and Designs for the Future; Paul T Vaitkus 7.
Thromboembolic Disease of Childhood; Leonardo R Brandao, Gabrielle deVeber,
Patricia Massicotte 8.
Thrombosis and Malignancy: An Overview; James T Loynes, LR Zacharski 9.The Role of Low Molecular Weight Heparins in the Management of Acute
Coronary Syndromes with or without
Percutanous Coronary Intervention; Luis Rios-Nogales, Santosh T Varghese, S
Soltes 10.Pharmaceutical Guidelines for New Anticoagulant and Antithrombotic
Agents; Wendy A Leong 11. An Update on
Thrombolytic Drugs; Omer Iqbal, Mahmut Tobu 12.Heparin Derived Oligosaccharides, Alzheimer’s Disease, and other Age
Related Neurological Disorders;
U Cornelli, S Lorens, J Lee, M Hejna, M Walzer, B Dudas, M Rose, M Cornelli, G
Torrio, L De Ambrosi, R Mervis, Q Ma,
J Fareed, I Hanin 13. Kininogen – an
Antithrombotic Protein In Vivo; Robert W Colman 14. The Mechanism of
Platelet Inhibition by ARG-GLY-ASP (RGD)-Containing Peptides; Joel S Bennett
15.New Anticoagulants
and Antithrombotic Agents: A Developmental Perspective;Jawed Fareed, Debra A
Hoppensteadt, Rodger L Bick 16.Statin Drugs As Antithrombotic, Prothrombotic, and other Agents; John W
Fenton II 17.Are All Low Molecular Weight Heparins The Same?; Shaker A Mousa 18.Heparin and Heparin-Derived Oligosaccharides: A Developmental
Perspective;
Qing Ma, Umberto Cornelli, Israel Hanin, John Lee, Debra Hoppensteadt, Walter
Jeske, Jawed Fareed 19.Dosing LMWHs In Special Populations; Jeffrey S Barrett, Kathryn R
Collison 20.Heparin In Thrombosis and Cancer: the Missing Link; Shaker A Mousa 21.The Role of Reactive Oxygen Species and Antioxidants in Platelet
Function; Jane E Freedman
Part II: Preclinical Perspective And IN VITRO
Studies
22.Thrombosis and Restenosis: Failure Modes in Preclinical In Vivo Studies
of Interventional Cardiovascular Devices;
John W Karanian, Jafar Vossoughi, William F Pritchard 23.The Effect of Restricted Blood Flow on Thrombolytic Activity of Locally
Delivered Plasmin: Comparison with TPA
In Rabbit Models of Venous and Arterial Thrombosis;
Gary Jesmok, Kyle Landskroner, Kathryn Taylor, Valery Novokhatny, TP
Zimmerman, Victor Marder 24.Biological and Functional Measurements of Platelet Function:
Implications for Dose Selection and Pharmacodynamic
Monitoring of GPIIb/IIIa Antagonists; Mary A Mascelli, Mark I Furman, David C
Sane 25.Emerging Views on the Biology of Heparin/ Heparan Sulfate;
Ram Sasisekharan, Zachary Shriver, Dongfang Liu, Mallik Sundaram, Ganesh
Venkataraman 26. Plasmin Dosages
that Induce Local Thrombolysis do not Cause Fibrinolytic Hemorrhage in the
Rabbit;
Victor J Marder, Kyle Landskroner, Valery Novokhatny, Thomas P Zimmerman,
Daphne Stewart, Mansze Kong,
Joel J Kanouse, Gary Jesmok 27.A Survey of Animal Models of Thrombosis and Bleeding; Adrienne
Racanelli 28.Tissue
Factor Pathway Inhibitor: Potential Implications in the Treatment of
Cardiovascular Disorders;
Debra A Hoppensteadt, Brigitte Kaiser, Jawed Fareed 29.Clinical
and Regulatory Issues with Embolic Protection Devices: The FDA Perspective;
Stuart Portnoy 30.Preclinical
Development of Specific Inhibitors of Coagulation Factor Xa; Uma Sinha 31.Evidence That Orally Administered Heparins Are Absorbed; Linda M
Hiebert 32. Comparative
Pharmacology of the Investigational Agent Neutralasetm (Heparinase
I) and Protamine In the Reversal of Heparin;
Robert Heft, Richard Broughton 33.
Overview of Plasmin as a Local
Thrombolytic Agent and In Vitro Studies Valery Novokhatny, Kathryn Taylor,
Kyle Landskroner, Gary Jesmok, Stephen R Petteway, Thomas Zimmerman
